Haw Par Corporation Ltd
SGX:H02

Watchlist Manager
Haw Par Corporation Ltd Logo
Haw Par Corporation Ltd
SGX:H02
Watchlist
Price: 15.61 SGD -0.76%
Market Cap: 3.5B SGD

Relative Value

The Relative Value of one H02 stock under the Base Case scenario is hidden SGD. Compared to the current market price of 15.61 SGD, Haw Par Corporation Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

H02 Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
33
vs Industry
12
Median 3Y
11
Median 5Y
11.9
Industry
2.6
vs History
47
vs Industry
35
Median 3Y
12.3
Median 5Y
13.4
Industry
21.7
vs History
39
vs Industry
8
Median 3Y
47.6
Median 5Y
51.9
Industry
16.6
vs History
38
vs Industry
11
Median 3Y
45.5
Median 5Y
55.3
Industry
22.5
vs History
12
vs Industry
68
Median 3Y
0.6
Median 5Y
0.7
Industry
2.3
vs History
28
vs Industry
15
Median 3Y
8.9
Median 5Y
9.8
Industry
2.9
vs History
28
vs Industry
13
Median 3Y
16.5
Median 5Y
18
Industry
5.5
vs History
34
vs Industry
36
Median 3Y
31.5
Median 5Y
35.4
Industry
13.1
vs History
38
vs Industry
40
Median 3Y
35
Median 5Y
39.5
Industry
16.6
vs History
44
vs Industry
10
Median 3Y
39.6
Median 5Y
42.6
Industry
15.8
vs History
57
vs Industry
12
Median 3Y
41.8
Median 5Y
82
Industry
19.1
vs History
12
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9

Multiples Across Competitors

H02 Competitors Multiples
Haw Par Corporation Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Haw Par Corporation Ltd
SGX:H02
3.5B SGD 13.7 13.8 38.5 42.1
US
Eli Lilly and Co
NYSE:LLY
954.7B USD 16.1 51.9 34.8 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
505.3B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
253.1B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.1 108.4 158.7
CH
Novartis AG
SIX:NOVN
203.4B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
246.3B USD 3.8 12.9 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.1
IE
Endo International PLC
LSE:0Y5F
202.5B USD 88.8 -70.5 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.7B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
SG
Haw Par Corporation Ltd
SGX:H02
Average P/E: 22.4
13.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -70.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average EV/EBITDA: 401.4
38.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average EV/EBIT: 1 711.6
42.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3